Cargando…

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.

Detalles Bibliográficos
Autores principales:	Bomze, David, Hasan Ali, Omar, Bate, Andrew, Flatz, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707013/ https://www.ncbi.nlm.nih.gov/pubmed/31436791 http://dx.doi.org/10.1001/jamaoncol.2019.3221

Ejemplares similares

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV
por: Gay, Cynthia L., et al.
Publicado: (2021)

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect
por: Liu, Mingyue, et al.
Publicado: (2022)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
por: Serna-Higuita, Lina María, et al.
Publicado: (2021)

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
por: Baxi, Shrujal, et al.
Publicado: (2018)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
por: Finazzi, T., et al.
Publicado: (2018)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
por: Gazzano, Marianne, et al.
Publicado: (2022)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021)

Methodology for computing the burden of disease of adverse events following immunization
por: McDonald, Scott A., et al.
Publicado: (2018)

OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
por: Pollack, Rena, et al.
Publicado: (2020)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Persistent mutation burden drives sustained anti-tumor immune responses
por: Niknafs, Noushin, et al.
Publicado: (2023)

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
por: Rogado, Jacobo, et al.
Publicado: (2020)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
por: Matsuoka, Hiroshi, et al.
Publicado: (2020)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
por: Mo, Shu-Fen, et al.
Publicado: (2023)

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
por: Dousset, Léa, et al.
Publicado: (2021)

Bifidobacterium longum RAPO Ameliorates Anti-tumor Efficacy and Immune-Related Adverse Events of Anti-PD-1 Therapy in a Mouse Model of Triple-Negative Breast Cancer
por: Kim, Hyeyoon, et al.
Publicado: (2022)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
por: Zhang, Xiaoyun, et al.
Publicado: (2022)

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition
por: Risbjerg, Rasmus Strøm, et al.
Publicado: (2020)

Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy
por: Huang, Xinyi, et al.
Publicado: (2021)

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
por: Goodman, Rachel S., et al.
Publicado: (2023)

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
por: Shimozaki, Keitaro, et al.
Publicado: (2020)

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2021)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
por: Griewing, Luisa Maria, et al.
Publicado: (2021)

Retrospective analysis of ocular adverse events with Clobetasol
por: Wang, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rfmpv1rj5h0nmj9v23lmgh0vg7